CBD-Derived Epidiolex Gains FDA Approval for Epilepsy

Share the love

In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet  syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures the Epidiolex. The drug is expected to cost between $2500 to $500 for a monthly supply.

An FDA advisory panel unanimously recommended in April that Epidiolex be approved for use in the United States.


Read more.

Leave a Reply